Stockreport

Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting

Spectrum Pharmaceuticals, Inc.  (SPPI) 
Last spectrum pharmaceuticals, inc. earnings: 2/27 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.sppirx.com/investor-relations
PDF Integrated efficacy and safety results in 643 patients were consistent with individual trial results (ADVANCE and RECOVER) The in [Read more]